Tacrolimus (FK506): Experience in dermatology

Dermatologic Therapy

Volumn 5, Issue , 1998, Pages 74-84

  Lawrence, Ira D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; INTERLEUKIN 2; TACROLIMUS;

ATOPIC DERMATITIS; DISEASE SEVERITY; DRUG FORMULATION; IMMUNOMODULATION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; PSORIASIS; REVIEW; SKIN DISEASE; STREPTOMYCES; T LYMPHOCYTE;

EID: 0031924122     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Sawden JM, Berth-Jones J, Ross JS et al. A Multicentre, double-blind, placebo-controlled crossover study to assess the efficacy and safety of cyclosporin in adult patients with severe refractory atopic dermatitis. Lancet 1991: 338: 137-140.
2. Ellis CN, Gorsulowsky DC, Hamilton TA et al. Cyclosporin improves psoriasis in a double-blind study. JAMA 1986: 256: 3110-3116.
3. Mrowietz U. The enigma of cyclosporin A treatment for psoriasis: systemic efficacy versus topical non-responsiveness. Acta Derm Venereol (Stockh) 1992: 72: 321-326.
4. Cowlson IH, Holden CA. Topical cyclosporin A in alopecia areata: failure of therapeutic effect due to lack of penetration. Br J Dermatol 1989: 121(Suppl 34): 53-54.
5. Sawada S, Suzuki G, Kawase Y, Takaku F. Novel immunosuppressive agent, FK506, in vitro effects on cloned T-cell activation. J Immunol 1987: 139: 1797-1803.
6. Package Insert, Prograf® (tacrolimus). Osaka, Japan: Fujisawa Pharmaceutical Company.
7. Bos JD, Smitt JHS. Atopic dermatitis. J Eur Acad Dermatol Venereol 1996: 7: 101-114.
8. Bieber T, Ring J. In vivo modulation of the high-affinity receptor of IgE (FcεRI) on human epidermal Langerhans cells. Int Arch Allergy Immunol 1992: 99: 204-207.
9. Michel G, Kemeny L, Homey B, Ruzicka T. FK506 in the treatment of inflammatory skin disease: promises and perspectives. Immunol Today 1996: 17: 106-108.
10. Barker JNWW. The immunopathology of psoriasis. Bailliere's Clin Rheumatol 1994: 8: 429-438.
11. Thomson AW, Nelesnik MA, Rilo HR et al. ICAM-1 and E-selectin expression in lesional biopsies of psoriasis patients responding to systemic FK506 therapy. Autoimmunity 1993: 25: 215-223.
12. Lemster BH, Carroll PB, Rilo HR et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 1995: 99: 148-154.
13. Kelly PA, Burckart GJ, Venkataramana R. Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm 1995: 52: 1521-1535.
14. Mori A, Suko M, Nishizaki Y et al. Regulation of interleukin-5 production by peripheral blood mononuclear cells from atopic patients with FK506, cyclosporin A and glucocorticoids. Int Arch Allergy Immunol 1994: 104(suppl 1): 32-35.
15. dePaulis A, Stellato C, Cirillo R et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J. Invest Dermatol 1992: 99: 723-728.
16. Eberlein-Konig B, Ruzicka T, Michel G et al. Inhibition of the in vitro histamine release (HR) from human basophils by the immunosuppressive drug FK506. J. Invest Dermatology 1993: 100: 446 (A62).
17. Nakagawa H, Etoh T, Ishibashi Y et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994: 344: 883.
18. Aoyama H, Tabata N, Tanaka M et al. Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment. Br J Dermatol 1995: 133: 492-500.
19. Alaiti S, Kang S, Fiedler V et al. Tacrolimus (FK506) Ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol (in press).
20. Ruzicka T, Bieber T, Schöpf E et al. A Short-term trial of tacrolimus ointment for atopic dermatitis. N Eng J Med 1997: 337: 816-821.
21. Boguniewicz M, Leung DYM, Fiedler V et al. Treatment of pediatric atopic dermatitis with tacrolimus ointment. J Allergy Clin Immunol 1997: 99: S478.
22. Jegasothy BV, Ackerman CD, Todo S et al. Tacrolimus (FK506) - A new therapeutic agent for severe recalcitrant psoriasis. Arch Dermatol 1992: 128: 781-785.
23. The European FK506 Study Group. Systemic tacrolimus (FK506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996: 132: 419-423.